Drug intelligence / Profile preview

Mycobacteriophage Muddy_HRMN0052

Development stage: Phase 1
Lead developer: Vancouver Coastal Health
Administration: Intravenous, Inhalation

Overview

Mycobacteriophage Muddy_HRMN0052 is a lytic bacteriophage under investigation as a potential therapeutic agent for lung infections caused by Mycobacterium abscessus. This phage therapy operates by specifically targeting and destroying bacteria through a process of cell lysis. It is currently in early-phase clinical development, with a Phase 1 trial evaluating its safety and efficacy, often in conjunction with conventional antimycobacterial therapies. This targeted mechanism of action offers a promising approach to overcome antibiotic resistance, a significant challenge in treating persistent mycobacterial infections.

Other names: phage Muddy

Targets

Trehalose

Beyond the preview

Go deeper on Mycobacteriophage Muddy_HRMN0052.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mycobacteriophage Muddy_HRMN0052.

Explore the full profile